News & Blog

March 28, 2024 | Press Release
ProJenX Announces Removal of Partial Clinical Hold for Prosetin Program by FDA
Read More
March 05, 2024 | Press Release
Immunitas Therapeutics to Present Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting
Read More
February 14, 2024 | Press Release
ProJenX Receives European Authorization for First Study of Prosetin in People Living with ALS
Read More
February 14, 2024 | Press Release
Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead
Read More
February 02, 2024 | Blog Post
2023 – A Year in Retrospect
Read More
January 31, 2024 | Blog Post
MEC in 4Q23: Pioneering the Future of Precision Medicine – More in 2024
Read More
January 18, 2024 | Press Release
Immunitas Therapeutics Appoints Annalisa D’Andrea, Ph.D., as Chief Scientific Officer
Read More
January 08, 2024 | Press Release
Pleno Deploys its RAPTOR Instrument Platform Available with TotalSeq™ Antibodies from BioLegend
Read More
January 05, 2024 | In The News
SonoThera’s CEO Ken Greenberg interviewed by Wilson Sonsini’s Dustin Luettgen in the latest edition of the Life Sciences Report
Read More
November 02, 2023 | Press Release
ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of Directors
Read More